Clinical TrialsThe Phase 3 CoMpass trial in early choroidal melanoma remains on track for full enrollment by year-end, supported by strong global engagement.
Financial PositionAURA reported $177.3 million in cash and cash equivalents, which they expect to provide runway into the first half of 2027.
Intellectual PropertyRecent IP developments, including a new formulation patent with potential exclusivity to 2046, further strengthen Aura’s competitive positioning.